Antibody CDR Loops As Ensembles in Solution Vs. Canonical Clusters from X-ray Structures
Overview
Affiliations
In the past decade, the relevance of antibodies as therapeutics has increased substantially. Therefore, structural and functional characterization, in particular of the complementarity-determining regions (CDRs), is crucial to the design and engineering of antibodies with unique binding properties. Various studies have focused on classifying the CDR loops into a small set of main-chain conformations to facilitate antibody design by assuming that certain sequences can only adopt a limited number of conformations. Here, we present a kinetic classification of CDR loop structures as ensembles in solution. Using molecular dynamics simulations in combination with strong experimental structural information, we observe conformational transitions between canonical clusters and additional dominant solution structures in the micro-to-millisecond timescale for all CDR loops, independent of length and sequence composition. Besides identifying all relevant conformations in solution, our results revealed that various canonical cluster medians actually belong to the same kinetic minimum. Additionally, we reconstruct the kinetics and probabilities of the conformational transitions between canonical clusters, and thereby extend the model of static canonical structures to reveal a dynamic conformational ensemble in solution as a new paradigm in the field of antibody structure design. CDR: Complementary-determining region; Fv: Antibody variable fragment; PCCA: Perron cluster analysis; tICA: Time-lagged independent component analysis; V: Heavy chain variable region; V: Light chain variable region.
Structural basis for antibody recognition of the proximal MUC16 ectodomain.
Lee K, Perry K, Xu M, Veillard I, Kumar R, Rao T J Ovarian Res. 2024; 17(1):41.
PMID: 38374055 PMC: 10875768. DOI: 10.1186/s13048-024-01373-9.
Madsen A, Mejias-Gomez O, Pedersen L, Morth J, Kristensen P, Jenkins T Comput Struct Biotechnol J. 2024; 23:199-211.
PMID: 38161735 PMC: 10755492. DOI: 10.1016/j.csbj.2023.11.056.
Tulika T, Pedersen R, Rimbault C, Ahmadi S, Rivera-de-Torre E, Fernandez-Quintero M Protein Sci. 2023; 32(12):e4821.
PMID: 37897425 PMC: 10659949. DOI: 10.1002/pro.4821.
Structure and Dynamics Guiding Design of Antibody Therapeutics and Vaccines.
Fernandez-Quintero M, Pomarici N, Fischer A, Hoerschinger V, Kroell K, Riccabona J Antibodies (Basel). 2023; 12(4).
PMID: 37873864 PMC: 10594513. DOI: 10.3390/antib12040067.
Guloglu B, Deane C Front Immunol. 2023; 14:1223802.
PMID: 37564639 PMC: 10410447. DOI: 10.3389/fimmu.2023.1223802.